School of Medical Sciences, University of Sydney, Sydney, Australia.
Department of Orthopedics, University Medical Center Utrecht, Utrecht, The Netherlands.
Trends Biotechnol. 2024 Jul;42(7):859-876. doi: 10.1016/j.tibtech.2024.01.001. Epub 2024 Feb 5.
Microcarrier expansion systems show exciting potential to revolutionise mesenchymal stromal cell (MSC)-based clinical therapies by providing an opportunity for economical large-scale expansion of donor- and patient-derived cells. The poor reproducibility and efficiency of cell expansion on commercial polystyrene microcarriers have driven the development of novel microcarriers with tuneable physical, mechanical, and cell-instructive properties. These new microcarriers show innovation toward improving cell expansion outcomes, although their limited biological characterisation and compatibility with dynamic culture systems suggest the need to realign the microcarrier design pathway. Clear headway has been made toward developing infrastructure necessary for scaling up these technologies; however, key challenges remain in characterising the wholistic effects of microcarrier properties on the biological fate and function of expanded MSCs.
微载体扩增系统通过为供体和患者来源细胞的经济大规模扩增提供机会，显示出了变革间充质基质细胞（MSC）为基础的临床治疗的令人兴奋的潜力。商业聚苯乙烯微载体上细胞扩增的重复性差和效率低，推动了具有可调物理、机械和细胞指令特性的新型微载体的发展。这些新的微载体在改善细胞扩增结果方面显示出了创新性，尽管它们对生物特性的有限表征以及与动态培养系统的兼容性表明需要重新调整微载体设计途径。在开发这些技术所需的基础设施方面已经取得了明显的进展；然而，在表征微载体特性对扩增MSC 的生物学命运和功能的整体影响方面，仍然存在关键挑战。
